Book contents
- Practical Psychopharmacology
- Practical Psychopharmacology
- Copyright page
- Dedication
- Contents
- Foreword
- Preface
- Abbreviations
- Part I General Principles
- 1 Core Concepts of Good Psychopharmacology
- 2 Targets of Treatment: Categories versus Dimensions of Psychopathology
- 3 Interpreting and Using the Literature: Integrating Evidence-Based Trials with Real-World Practice
- 4 Placebo and Nocebo Effects
- 5 Tailoring the Fit: Moderators and Mediators of Treatment Outcome
- 6 Complex Regimens and Rationale-Based Combination Drug Therapies
- 7 Laboratory Values and Psychiatric Symptoms: What to Measure, What Not to Measure, and What to Do With The Results
- 8 Pharmacogenetics: When Relevant, When Not
- 9 Cross-tapering and the Logistics of Drug Discontinuation
- 10 Managing Major Adverse Drug Effects: When to Avoid, Switch, or Treat Through
- 11 Novel Drug Therapeutics: Nutraceuticals, Steroids, Probiotics, and Other Dietary Supplements
- 12 Human Diversity and Considerations in Special Populations
- Part II Targets of Pharmacotherapy
- References
- Index
10 - Managing Major Adverse Drug Effects: When to Avoid, Switch, or Treat Through
from Part I - General Principles
Published online by Cambridge University Press: 19 October 2021
- Practical Psychopharmacology
- Practical Psychopharmacology
- Copyright page
- Dedication
- Contents
- Foreword
- Preface
- Abbreviations
- Part I General Principles
- 1 Core Concepts of Good Psychopharmacology
- 2 Targets of Treatment: Categories versus Dimensions of Psychopathology
- 3 Interpreting and Using the Literature: Integrating Evidence-Based Trials with Real-World Practice
- 4 Placebo and Nocebo Effects
- 5 Tailoring the Fit: Moderators and Mediators of Treatment Outcome
- 6 Complex Regimens and Rationale-Based Combination Drug Therapies
- 7 Laboratory Values and Psychiatric Symptoms: What to Measure, What Not to Measure, and What to Do With The Results
- 8 Pharmacogenetics: When Relevant, When Not
- 9 Cross-tapering and the Logistics of Drug Discontinuation
- 10 Managing Major Adverse Drug Effects: When to Avoid, Switch, or Treat Through
- 11 Novel Drug Therapeutics: Nutraceuticals, Steroids, Probiotics, and Other Dietary Supplements
- 12 Human Diversity and Considerations in Special Populations
- Part II Targets of Pharmacotherapy
- References
- Index
Summary
We hope that things have changed for the better since the time of Sir Francis Bacon’s seventeenth-century appraisal of medical treatment risks and benefits. Drugs themselves may not know the differences between the beneficial versus adverse effects they may exert, but prescribers should. All substances, even placebos, can cause negative effects in the minds and bodies of those who consume them, depending on expectations (e.g., past experiences, perceptions of help versus harm), underlying psychopathology (e.g., anxiety, somatization, paranoia), psychological dimensions (e.g., an external locus of control, suggestibility) as well as pharmacokinetics (e.g., delayed metabolic clearance) and, last but not least, pharmacodynamics.
- Type
- Chapter
- Information
- Practical PsychopharmacologyTranslating Findings From Evidence-Based Trials into Real-World Clinical Practice, pp. 192 - 220Publisher: Cambridge University PressPrint publication year: 2021